We have three RESTORE Layer 1 candidates this month. None of them get the same molecules first.

The first is the patient we walked through last issue — the mid-40s recovery story. Normal differential, workouts feeling like less. SS-31 and NAD+ went in first. MOTS-c is held until week 5. The signal we're repairing is the membrane scaffold and the coenzyme pool. We don't ask the cell to build new mitochondria until the foundation is ready.

The second is a man in his late 50s who hasn't fully recovered from a long-COVID episode eighteen months back. The energy curve never returned. A cognitive-fog signature he didn't have before. Standard infectious and metabolic workup negative — thyroid, CRP, HbA1c, testosterone all normal. He's already on tirzepatide for an unrelated metabolic picture. At his next protocol revision we're staging the cognitive-metabolic layer we planned from the start: MOTS-c and methylene blue (BETA-gated, after a G6PD screen clears) lead; SS-31 and NAD+ run in support. Biogenesis push and alternative-electron-route are the two most directly studied levers in post-viral cellular recovery — that's the rationale for leading with them in this phenotype.

The third is a man on a high-dose SSRI. Methylene blue is an absolute contraindication — FDA black box, serotonin syndrome risk, no dosing threshold that makes it safe with concurrent serotonergic medications. We don't gate this one. We omit. SS-31, NAD+, and MOTS-c at week 5 give us three of the four mechanisms. The oral foundation runs without MB.

Order isn't arbitrary. It follows the lab signal and the comorbidity that tipped the question. We don't deploy all the cellular tools at once.

NAD+, MOTS-c, and SS-31 don't do the same thing. They live at different points on the same machine — and the orals fill in the gaps.

The machine

Every cell runs on ATP. Mitochondria make it via the electron transport chain (ETC) — a sequence of protein complexes on the inner membrane where electrons flow, a proton gradient builds, and ATP synthase spins out energy currency. The chain sits on a structural scaffold: cardiolipin, a phospholipid that holds the ETC complexes in organized supercomplexes. Mitochondria also carry their own genome (mtDNA) and broadcast their status via signaling peptides — mitokines — that circulate in blood and enter the nucleus under stress. The peptides we use don't all live in the same neighborhood of this machine.

NAD+ — the coenzyme address

NAD+ (nicotinamide adenine dinucleotide) is the electron carrier that powers the ETC at Complex I, and the substrate for sirtuin-mediated DNA repair throughout the cell. Levels fall 40–60% between ages 40 and 70. The driver isn't an accelerating disease — it's a calendar process: rising CD38 ectoenzyme activity on immune cells consumes NAD+ as part of low-grade inflammatory signaling, and the coenzyme pool doesn't keep up.

At KEH we use NAD+ by SubQ injection — 100 mg twice weekly — because injectable bypasses the conversion steps oral precursors (NR, NMN) require. The precursors have the deepest RCT data; injectable mechanism is sound but clinical-endpoint evidence is thinner. We say that plainly. We don't know yet whether SubQ NAD+ shifts hard outcomes. We're watching.

MOTS-c — the biogenesis address

MOTS-c activates AMPK — the cell's master energy sensor — and drives PGC-1α, the master regulator of mitochondrial biogenesis. It is how exercise signals the cell to build more mitochondria, recapitulating that pathway on the identical molecular mechanism. Encoded within the mitochondrial genome itself, MOTS-c functions as a mitokine: it circulates in blood, rises with exercise, declines with age, and under metabolic stress translocates to the nucleus to modulate gene expression directly — making it both a circulating hormone and a nuclear regulator. What distinguishes it from purely preclinical peptides is the human genetic data: a gain-of-function variant, MT-RNR1 A1382C, is associated in population studies with improved longevity, lower type 2 diabetes prevalence, and reduced all-cause mortality — a causal signal most investigational peptides don't have. At KEH, MOTS-c enters the RESTORE cycle at week 5 — not week 1.

SS-31 — the membrane address

SS-31 (elamipretide) is a tetrapeptide that concentrates more than 1,000-fold in mitochondria. It binds cardiolipin and stabilizes the ETC supercomplexes cardiolipin holds together.

The mechanistic note worth making explicitly: SS-31 has no measurable effect on healthy mitochondria. Its benefit is proportional to existing dysfunction. This is unusual and clinically important — it means the drug is doing specific repair work on a damaged substrate. When cardiolipin integrity is compromised and supercomplexes are disorganized, SS-31 restores them. When they aren't, the molecule passes through without consequence.

SS-31 has the strongest human evidence of the three injectables. FDA granted accelerated approval for Barth syndrome — a genetic cardiolipin deficiency disease — in September 2025. The ReNEW Phase 3 trial in AMD is ongoing; the heart failure Phase 2 trial missed its primary endpoint. The Barth approval provides an evidence anchor that MOTS-c and injectable NAD+ don't yet have. At KEH we dose 10 mg SubQ daily five times a week.

Four orals filling in the gaps

The three injectables are the high-amplitude layer — cycled, SubQ, time-limited. Below them runs a continuous oral foundation that hits four additional addresses on the same organelle.

Urolithin A drives mitophagy — the selective clearance of damaged mitochondria. The mechanism class is distinct from everything else in the stack: clearance, not repair or production. A randomized controlled trial in older adults showed 12% improvement in muscle strength. That's the only RCT in this category.

CoQ10 (ubiquinol form) is the natural electron carrier between Complex I/II and Complex III. Levels decline with age and are depleted directly by statins — for any folk on a statin, replacement isn't optional. Q-SYMBIO, a randomized heart failure trial, showed mortality benefit.

PQQ (pyrroloquinoline quinone) is the only component in this stack that creates new mitochondria — biogenesis, not just repair of existing ones. It drives this via the CREB/PGC-1α pathway, which is upstream-distinct from MOTS-c's AMPK route: both converge on PGC-1α, but through different cellular sensors. Oral, daily, continuous. Human data are limited; the mechanism is sound.

Methylene blue acts as an alternative electron carrier at low doses — bypassing dysfunctional sites at Complex I/II and donating electrons directly to cytochrome c. A different route through the ETC, not a redundant one. Two screens before it touches any protocol: G6PD status (MB can precipitate hemolytic anemia in G6PD-deficient folks) and a full serotonergic medication screen. SSRIs, SNRIs, MAOIs, and triptans are absolute contraindications — FDA black box, serotonin syndrome.

Why complementary, not redundant

Different addresses. Different timescales. Different mechanisms. The injectables are high-amplitude and cycled — the acute repair signal is time-limited. The orals are continuous because mitochondrial maintenance is not a pulse intervention. Hitting every bottleneck with a single tool requires higher doses, accepts more off-target exposure, and loses the specificity you get from matching each mechanism to its right compound.

The table maps the full stack.

All injectable peptides are prescription compounds, evaluated and dosed under physician supervision, sourced through a 503A-licensed compounding pharmacy, and available in select states.

Cellular tools don't replace metabolic ones. They sit underneath them — and the order in which we add them is the next conversation.

Kinetic Edge Health is a physician-led telehealth practice focused on longevity, metabolic optimization, and urological wellness. If a stack in this issue is relevant to you, book a strategy session.

Short-form dispatches on longevity, metabolic health, and men’s performance — from the founder of Kinetic Edge Health.

Telehealth practice. Prescription compounds and peptides require physician evaluation. Not available in all states.

kineticedgehealth.com · Cleveland, OH

© 2026 Kinetic Edge Health, Inc. · All rights reserved.

Not for you anymore?

Use the unsubscribe link below to stop future issues.